Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel germline PAX5 single exon deletion in a pediatric patient with precursor B-cell leukemia.
van Engelen N, Roest M, van Dijk F, Sonneveld E, Bladergroen R, van Reijmersdal SV, van der Velden VHJ, Hoogeveen PG, Kors WA, Waanders E, Jongmans MCJ, Kuiper RP. van Engelen N, et al. Among authors: van reijmersdal sv, van dijk f, van der velden vhj. Leukemia. 2023 Sep;37(9):1908-1911. doi: 10.1038/s41375-023-01991-0. Epub 2023 Aug 5. Leukemia. 2023. PMID: 37543654 Free PMC article. No abstract available.
DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers.
Staal FJ, van der Burg M, Wessels LF, Barendregt BH, Baert MR, van den Burg CM, van Huffel C, Langerak AW, van der Velden VH, Reinders MJ, van Dongen JJ. Staal FJ, et al. Leukemia. 2003 Jul;17(7):1324-32. doi: 10.1038/sj.leu.2402974. Leukemia. 2003. PMID: 12835720
Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL.
Szczepański T, van der Velden VH, Raff T, Jacobs DC, van Wering ER, Brüggemann M, Kneba M, van Dongen JJ. Szczepański T, et al. Leukemia. 2003 Nov;17(11):2149-56. doi: 10.1038/sj.leu.2403081. Leukemia. 2003. PMID: 14576730
Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program.
van der Velden VH, Boeckx N, Gonzalez M, Malec M, Barbany G, Lion T, Gottardi E, Pallisgaard N, Beillard E, Hop WC, Hoogeveen PG, Gabert J, van Dongen JJ; Europe Against Cancer Program. van der Velden VH, et al. Leukemia. 2004 Apr;18(4):884-6. doi: 10.1038/sj.leu.2403309. Leukemia. 2004. PMID: 14961029 Free article. No abstract available.
245 results